Resilience Partners with Parvus Therapeutics for PVT401
National Resilience, Inc. (Resilience) has announced an exciting development in its collaboration with Parvus Therapeutics. This partnership focuses on advancing PVT401, a novel drug candidate specifically designed to address Inflammatory Bowel Disease (IBD). The collaboration signifies a significant advancement in Resilience's mission of enhancing access to complex therapeutics.
Building on Past Success
This latest announcement builds on the successful development and manufacturing of the Parvus clinical-stage drug candidate PVT201 at Resilience. The continued collaboration highlights both companies’ commitment to facilitating patient access to innovative therapeutic options.
Expertise and Innovation
Dr. Susan Billings, Chief Commercial Officer at Resilience, expressed pride in strengthening their partnership with Parvus. “This collaboration underscores Resilience’s dedication to empowering the development of transformative therapies and manufacturing solutions for complex therapeutics. Together with Parvus, we aim to bring innovative medicines like PVT401 closer to patients, addressing critical unmet needs in autoimmune diseases,” said Dr. Billings.
Transitioning to Clinical Stage
Louis Demers, Senior Vice President of Technical Operations at Parvus, recognized the valuable contributions of Resilience: “Our collaboration with Resilience provided critical development expertise and manufacturing capability we needed to transition from a preclinical to clinical-stage company. We look forward to working with Resilience to elevate our platform technology manufacturing capability and specifically advance PVT401, our second to clinical trial drug candidate.”
About Resilience
Founded in 2020, Resilience is a technology-driven biomanufacturing company committed to broadening access to complex therapies. The company focuses on creating a sustainable network for high-tech, end-to-end manufacturing solutions that ensure rapid, safe, and scalable production of modern treatments. By continually enhancing the science of biopharmaceutical manufacturing and development, Resilience empowers its partners to concentrate on breakthrough discoveries that benefit patients and protect biopharmaceutical supply chains from future disruptions.
About Parvus Therapeutics
Parvus is a private clinical-stage company working on pioneering peptide-major histocompatibility complex (pMHC) nanomedicine candidates aimed at producing antigen-specific Treg cells. This innovative approach shows potential in halting autoimmune diseases and restoring immune tolerance without affecting systemic immunity. One of their leading candidates, PVT201, is currently in a Phase 1/2 clinical trial, targeting liver autoimmune diseases, while PVT401 addresses inflammatory bowel disease. Other pMHC drug candidates are under development for many conditions, including type 1 diabetes and multiple sclerosis.
Frequently Asked Questions
What is the goal of the collaboration between Resilience and Parvus?
The goal is to advance the development of PVT401, a drug candidate for treating Inflammatory Bowel Disease (IBD).
When was Resilience founded?
Resilience was founded in 2020 and has quickly become a leader in biomanufacturing.
What is PVT401 designed to treat?
PVT401 is designed to target Inflammatory Bowel Disease (IBD), offering a new therapeutic option for this condition.
What expertise does Resilience bring to the partnership?
Resilience brings critical development expertise and advanced manufacturing capabilities, essential for transitioning drug candidates to clinical stages.
What other diseases are Parvus’s candidates targeting?
Parvus is developing nanomedicines for various autoimmune conditions, including type 1 diabetes, rheumatoid arthritis, and multiple sclerosis.
